Similarly, recent studies have suggested that AML patients with concomitant DNMT3A R882+/FLT3-ITD+/NPM1+ mutations had a very poor prognosis, and allo-HSCT could moderately improve their survival [62, 63]. Here, FLT3 is linked to acute myeloid leukemia.